Nuveen
ACAD icon

Nuveen’s Acadia Pharmaceuticals ACAD Stock Holding History

Nuveen’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-51,500
Closed -$1K – 3351
2021
Q1 		$1K Buy
+51,500
New +$2.27M ﹤0.01% 3358
2020
Q4 		– Sell
-61,200
Closed -$3K – 3303
2020
Q3 		$3K Buy
+61,200
New +$2.64M ﹤0.01% 3277

Other funds holding ACAD

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Public Sector Pension Investment Board (PSP Investments)
Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $45.4B AUM 34.02% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Nuveen's ACAD Position: Q3 2026 in Review

Nuveen reduced its Acadia Pharmaceuticals (ACAD) stake by 1.6% in Q3 2026, selling an estimated $585K and leaving 1,326,414 shares worth $26.7M. The position accounts for 0.01% of the portfolio, ranked #1066.

Nuveen first reported a position in ACAD in Q4 2013 and has held it in 35 quarters since. The position peaked at $94M in Q4 2019. 179 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Nuveen held 1,326,414 shares of Acadia Pharmaceuticals worth $26.7M as of Q3 2026.
  • Nuveen sold 21,778 Acadia Pharmaceuticals shares in Q3 2026, an estimated $585K.
  • Acadia Pharmaceuticals made up 0.01% of Nuveen's portfolio in Q3 2026, its #1066 holding.
  • Nuveen first reported a position in Acadia Pharmaceuticals in Q4 2013 and has held it in 35 quarters since.
  • Nuveen's Acadia Pharmaceuticals position peaked at $94M in Q4 2019.
  • 179 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.